Aim: We investigated the association of peritoneal glucose exposure and dialysis exchange number with peritonitis outcome in patients undergoing continuous ambulatory peritoneal dialysis (CAPD). Methods: The first episodes of bacterial peritonitis were retrospectively analyzed in 187 CAPD patients. Peritoneal glucose exposure was calculated based on PD prescription at the onset of peritonitis. Results: Patients with peritoneal glucose exposure ≤140 g/day showed a higher and complete cure rate of peritonitis (66 vs. 51.7%, p = 0.047), lower occurrence of relapsing/recurrent peritonitis (10.0 vs. 21.8%, p = 0.026) and catheter removal (14.0 vs. 26.4%, p = 0.033). Patients who exchanged more than three times every day demonstrated marginally higher catheter removal rate (24.1 vs. 13.0%, p = 0.085). Logistic analysis indicated that peritoneal glucose exposure >140 g/day was an independent predictor for relapsing/recurrent peritonitis (RR: 1.959, p = 0.042). Conclusion: High peritoneal glucose exposure is associated with increased incidence of relapsing/recurrent peritonitis in CAPD patients.

Keywords:
Peritoneal dialysis, Bacterial peritonitis, Peritoneal glucose exposure, Dialysis exchange number
1.
Li PK, Szeto CC, Piraino B, Bernardini J, Figueiredo AE, Gupta A, Johnson DW, Kuijper EJ, Lye WC, Salzer W, Schaefer F, Struijk DG; International Society for Peritoneal Dialysis: Peritoneal dialysis-related infections recommendations: 2010 update. Perit Dial Int 2010;30:393-423.
2.
Boudville N, Kemp A, Clayton P, Lim W, Badve SV, Hawley CM, McDonald SP, Wiggins KJ, Bannister KM, Brown FG, Johnson DW: Recent peritonitis associates with mortality among patients treated with peritoneal dialysis. J Am Soc Nephrol 2012;23:1398-1405.
3.
Brown F, Gulyani A, McDonald S, Hurst K: 35th Annual Report 2012: Australia and New Zealand Dialysis and Transplant Registry. South Australia, Adelaide, 2013.
4.
Pajek J, Hutchison AJ, Bhutani S, Brenchley PE, Hurst H, Perme MP, Summers AM, Vardhan A: Outcomes of peritoneal dialysis patients and switching to hemodialysis: a competing risks analysis. Perit Dial Int 2014;34:289-298.
5.
Yung S, Chan TM: Pathophysiological changes to the peritoneal membrane during PD-related peritonitis: the role of mesothelial cells. Mediators Inflamm 2012;2012:484167.
6.
Mortier S, De Vriese AS, McLoughlin RM, Topley N, Schaub TP, Passlick-Deetjen J, Lameire NH: Effects of conventional and new peritoneal dialysis fluids on leukocyte recruitment in the rat peritoneal membrane. J Am Soc Nephrol 2003;14:1296-1306.
7.
Witowski J, Wisniewska J, Korybalska K, Bender TO, Breborowicz A, Gahl GM, Frei U, Passlick-Deetjen J, Jörres A: Prolonged exposure to glucose degradation products impairs viability and function of human peritoneal mesothelial cells. J Am Soc Nephrol 2001;12:2434-2441.
8.
Posthuma N, ter Wee P, Donker AJ, Dekker HA, Oe PL, Verbrugh HA: Peritoneal defense using icodextrin or glucose for daytime dwell in CCPD patients. Perit Dial Int 1999;19:334-342.
9.
Cho Y, Badve SV, Hawley CM, McDonald SP, Brown FG, Boudville N, Bannister KM, Clayton PA, Johnson DW: Association of biocompatible peritoneal dialysis solutions with peritonitis risk, treatment, and outcomes. Clin J Am Soc Nephrol 2013;8:1556-1563.
10.
Johnson DW, Brown FG, Clarke M, Boudville N, Elias TJ, Foo MW, Jones B, Kulkarni H, Langham R, Ranganathan D, Schollum J, Suranyi M, Tan SH, Voss D; balANZ Trial Investigators: Effects of biocompatible versus standard fluid on peritoneal dialysis outcomes. J Am Soc Nephrol 2012;23:1097-1107.
11.
Montenegro J, Saracho R, Gallardo I, Martínez I, Muñoz R, Quintanilla N: Use of pure bicarbonate-buffered peritoneal dialysis fluid reduces the incidence of CAPD peritonitis. Nephrol Dial Transplant 2007;22:1703-1708.
12.
Lam D, Bargman JM: Peritonitis in the patient on peritoneal dialysis: does the composition of the dialysis fluid make a difference? Clin J Am Soc Nephrol 2013;8:1471-1473.
13.
Tobudic S, Kratzer C, Poeppl W, Vychytil A, Burgmann H: Impact of various peritoneal dialysis solutions on the growth of common bacterial and yeast pathogens. Perit Dial Int 2011;31:688-692.
14.
Morton AR, Evans G, Shannon A, Zoutman D: Growth of coagulase negative staphylococci in peritoneal dialysate fluid. Effect of calcium concentration. ASAIO J 1994;40:M431-M434.
15.
McDonald WA, Watts J, Bowmer MI: Factors affecting Staphylococcus epidermidis growth in peritoneal dialysis solutions. J Clin Microbiol 1986;24:104-107.
16.
Tuomanen E, Cozens R, Tosch W, Zak O, Tomasz A: The rate of killing of Escherichia coli by beta-lactam antibiotics is strictly proportional to the rate of bacterial growth. J Gen Microbiol 1986;132:1297-1304.
17.
Hermsen ED, Hovde LB, Hotchkiss JR, Rotschafer JC: Increased killing of staphylococci and streptococci by daptomycin compared with cefazolin and vancomycin in an in vitro peritoneal dialysate model. Antimicrob Agents Chemother 2003;47:3764-3767.
18.
Zelenitsky S, Franczuk C, Fine A, Ariano R, Harding G: Antibiotic tolerance of peritoneal bacterial isolates in dialysis fluids. J Antimicrob Chemother 2002;49:863-866.
19.
Li PK, Chow KM: Infectious complications in dialysis - epidemiology and outcomes. Nat Rev Nephrol 2011;8:77-88.
20.
Davies SJ, Phillips L, Naish PF, Russell GI: Peritoneal glucose exposure and changes in membrane solute transport with time on peritoneal dialysis. J Am Soc Nephrol 2001;12:1046-1051.
21.
Jiang N, Qian J, Lin A, Lindholm B, Axelsson J, Yao Q: Initiation of glucose-based peritoneal dialysis is associated with increased prevalence of metabolic syndrome in non-diabetic patients with end-stage renal disease. Blood Purif 2008;26:423-428.
22.
Mehrotra R, de Boer IH, Himmelfarb J: Adverse effects of systemic glucose absorption with peritoneal dialysis: how good is the evidence? Curr Opin Nephrol Hypertens 2013;22:663-668.
23.
Johnson DW, Brown FG, Clarke M, Boudville N, Elias TJ, Foo MW, Jones B, Kulkarni H, Langham R, Ranganathan D, Schollum J, Suranyi MG, Tan SH, Voss D; balANZ Trial Investigators: The effects of biocompatible compared with standard peritoneal dialysis solutions on peritonitis microbiology, treatment, and outcomes: the balANZ trial. Perit Dial Int 2012;32:497-506.
24.
Liu YL, Huang CC, Kao MT: Residual renal function predicts outcome of fungal peritonitis in peritoneal dialysis patients. Perit Dial Int 2006;26:407-409.
25.
Panichi V, Migliori M, De Pietro S, Taccola D, Bianchi AM, Giovannini L, Norpoth M, Metelli MR, Cristofani R, Bertelli AA, Sbragia G, Tetta C, Palla R, Colombo R: C-reactive protein and interleukin-6 levels are related to renal function in predialytic chronic renal failure. Nephron 2002;91:594-600.
26.
Moon SJ, Han SH, Kim DK, Lee JE, Kim BS, Kang SW, Choi KH, Lee HY, Han DS: Risk factors for adverse outcomes after peritonitis-related technique failure. Perit Dial Int 2008;28:352-360.
27.
Chow KM, Szeto CC, Kwan BC, Pang WF, Ma T, Leung CB, Law MC, Li PK: Randomized controlled study of icodextrin on the treatment of peritoneal dialysis patients during acute peritonitis. Nephrol Dial Transplant 2014;29:1438-1443.
© 2015 S. Karger AG, Basel
2015
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.